AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · IEX Real-Time Price · USD
0.365
-0.005 (-1.43%)
Jul 22, 2024, 10:12 AM EDT - Market open

AIM ImmunoTech Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019 2018 - 1995
Cash & Equivalents
3.35.4427.0532.0938.51.47
Upgrade
Short-Term Investments
7.657.637.1416.180.57.31
Upgrade
Cash & Cash Equivalents
10.9413.0734.1948.27398.78
Upgrade
Cash Growth
-64.53%-61.77%-29.17%23.76%344.32%380.99%
Upgrade
Receivables
00000.030.04
Upgrade
Other Current Assets
0.361.492.131.951.271.62
Upgrade
Total Current Assets
11.3114.5636.3250.2140.3110.45
Upgrade
Property, Plant & Equipment
0.880.821.024.26.657.27
Upgrade
Long-Term Investments
000015.380
Upgrade
Goodwill and Intangibles
2.312.311.941.971.51.15
Upgrade
Other Long-Term Assets
1.691.691.21.320.751.89
Upgrade
Total Long-Term Assets
4.884.834.177.4924.2710.31
Upgrade
Total Assets
16.1919.3840.4957.764.5820.75
Upgrade
Accounts Payable
6.576.440.380.20.380.47
Upgrade
Current Debt
1.860.220.180.040.280.25
Upgrade
Other Current Liabilities
1.451.990.810.440.440.4
Upgrade
Total Current Liabilities
9.888.651.360.671.11.13
Upgrade
Long-Term Debt
1.490.50.660.112.016.13
Upgrade
Other Long-Term Liabilities
0000.040.180.06
Upgrade
Total Long-Term Liabilities
1.490.50.660.152.196.19
Upgrade
Total Liabilities
11.369.152.020.823.297.31
Upgrade
Total Debt
3.350.720.840.152.296.38
Upgrade
Debt Growth
311.55%-14.22%461.74%-93.48%-64.18%7.68%
Upgrade
Retained Earnings
-415.33-409.51-380.55-361.1-341.97-327.57
Upgrade
Comprehensive Income
0000-0.050
Upgrade
Shareholders' Equity
4.8310.2338.4756.8861.2913.44
Upgrade
Net Cash / Debt
7.5912.3533.3548.1236.722.4
Upgrade
Net Cash / Debt Growth
-74.72%-62.97%-30.69%31.05%1431.15%-
Upgrade
Net Cash Per Share
0.150.250.691.021.150.66
Upgrade
Working Capital
1.435.934.9649.5439.219.32
Upgrade
Book Value Per Share
0.100.210.801.201.933.69
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).